

The pending claims are 1-14, and 18-20. Please cancel claim 2, 3, and 11 and amend pending claims 1, 4-10, 12-14, and 18 - 20 as follows. The Listing of Claims replaces all prior versions of claims in the application.

Listing of Claims

1. (Currently amended) A stabilized immunostimulatory microparticulate complex comprising a cationic peptide immunogen wherein the peptide immunogen comprises a target B cell antigen or a CTL epitope and a T helper cell epitope and anionic CpG oligonucleotide wherein the cationic peptide immunogen has a net positive charge at a pH in the range of 5.0 to 8.0 calculated by assigning a +1 charge for each lysine (K), arginine (R) or histidine (H), a -1 charge for each aspartic acid (D) or glutamic acid (E) and a charge of 0 for all other amino acids in the peptide immunogen and wherein the anionic CpG oligonucleotide has a net negative charge at a pH in the range of 5.0-8.0 and is a single-stranded DNA comprising 8 to 64 nucleotide bases with a repeat of a cytosine-guanidine motif and the number of repeats of the CpG motif is in the range of 1 to 10.
2. (Currently canceled) ~~The immunostimulatory complex of claim 1, wherein the cationic peptide immunogen is a synthetic peptide.~~
3. (Currently canceled) ~~The immunostimulatory complex of claim 2, wherein the peptide immunogen comprises a target B cell or a CTL epitope, and a T helper cell epitope.~~
4. (Currently amended) The immunostimulatory microparticulate complex of claim 1, wherein the cationic peptide immunogen is a mixture of synthetic peptide immunogens.
5. (Currently amended) The immunostimulatory microparticulate complex of claim 1, wherein the net positive charge of the cationic synthetic peptide immunogen is at least +2.

6. (Currently amended) The immunostimulatory microparticulate complex of claim 4, wherein the average net positive charge of the mixture of synthetic peptide immunogens is at least +2.
7. (Currently amended) The immunostimulatory particulate complex of claim 45 or 6, wherein the net negative charge of the anionic oligonucleotide is at least -2.
8. (Currently amended) The immunostimulatory microparticulate complex of claim 1, wherein the CpG oligonucleotide is a single-stranded DNA molecules with 18-48 nucleotide bases and the number of repeats of CpG motif therein in the range of 3 to 8.
9. (Currently amended) The immunostimulatory microparticulate complex of claim 1, wherein the CpG oligonucleotide has the formula: 5' X¹CGX² 3' wherein C and G are unmethylated; and X¹ is selected from the group consisting of A (adenine), G (guanine) and T (thymine); and X² is C (cytosine) or T (thymine).
10. (Currently amended) The immunostimulatory microparticulate complex of claim 1, wherein the CpG oligonucleotide has the formula: 5'(X³)₂CG(X⁴)₂ 3' wherein C and G are unmethylated; and X³ is selected from the group consisting of A or G; and X⁴ is C or T.
11. (Currently cancelled) ~~The immunostimulatory complex of claim 1, wherein the CpG oligonucleotide is modified with a phosphorothioate.~~
12. (Currently amended) The immunostimulatory microparticulate complex of claim 14, wherein CpG oligonucleotide is selected from a group consisting of 5' TCG TCG TTT TGT CGT TTT GTC GTT TTG TCG TT 3' (CpG1) SEQ ID NO: 1, a 32 base length oligomer, and 5'nTC GTC GTT TTG TCG TTT TGT CGT T 3' (CpG2) SEQ ID NO: 2, a 24 base length oligomer plus an phosphorothioate group designated as n.

13. (Currently amended) The immunostimulatory microparticulate complex of claim 12, wherein CpG oligonucleotide is 5' TCG TCG TTT TGT CGT TTT GTC GTT TTG TCG TT 3' (CpG1) SEQ ID NO: 1.
14. (Currently amended) The immunostimulatory microparticulate complex of claim 12, wherein CpG oligonucleotide is 5'nTC GTC GTT TTG TCG TTT TGT CGT T 3' (CpG2) SEQ ID NO: 2, a 24 base length oligomer plus a phosphorothioate group designated as n.
- 15.-17. (Withdrawn)
18. (Currently amended) The immunostimulatory microparticulate complex of claim 12, wherein the cationic peptide immunogen is a synthetic peptide ~~derived from LHRH~~ wherein LHRH is conjugated to a T helper cell epitope.
19. (Currently amended) The immunostimulatory microparticulate complex of claim 18, wherein the ~~synthetic peptide~~ the cationic immunogen ~~derived from LHRH~~ is selected from the group consisting of SEQ ID NO: 7, 8 and 9 and a mixture thereof.
20. (Currently amended) The immunostimulatory microparticulate complex of claim 19, wherein the ~~mixture~~ the cationic immunogen is a mixture of SEQ ID NO: 7, 8, and 9.
- 21.-75. (Withdrawn)